Responses
Oral Presentations
Abstract session: RA therapy beyond TNF inhibition
OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
Compose a Response to This Article
Other responses
No responses have been published for this article.